Home » Newsletters » BioWorld Science

BioWorld Science

April 18, 2002

View Archived Issues

Euroscreen acquires license to hormone receptor technology

Orally active VEGFR tyrosine kinase inhibitor RWJ-417975 exerts antitumor activity in mouse models

Improved HIV protease inhibitors discovered at Merck & Co.

Histamine H3 receptor agonist discovered by European team

Clinical trials of drugs in development for neurological disorders presented in Denver

New clinical trial results with mitoxantrone reported at this week's AAN meeting

Clinical trials with botulinum toxins reported at the AAN meeting

Prolifix identifies hydroxamate-based inhibitors of HDAC with antitumor activity

VEGFR tyrosine kinase inhibitor enters clinical testing based on preclinical results

Xcytrin to enter confirmatory phase III trial in lung cancer patients

Human Genome Sciences updates achievements in first quarter of 2002

Patient treatment begun in phase I/IIa trial of ZYC-300

Discovery Partners and Xenon Genetics collaborate on metabolic syndrome drug discovery

Consensus awarded SBIR grant for AIDS drug development

Trial initiated for Reolysin in prostate cancer

AGIX-4207 I.V. well tolerated and safe in phase I trial

Phase III trial of high-dose Betaferon/Betaseron planned

Biogen launches long-term study comparing Avonex and Rebif in MS

NDA submitted for Eligard 30 mg for advanced prostate cancer

New bicyclic alphavbeta3 and/or alphavbeta5 antagonists under study at Pharmacia

Agents for cardiovascular disorders developed at Sanofi-Synthelabo

Pola identifies compounds that reverse multidrug resistance in cancer and infections

Dual adenosine A1 and A2A receptor antagonists and their use described in recent patent

GSK presents new series of potent and selective COX-2 inhibitors

Recent patent describes synthesis, activity and use of polyamine AMPA receptor antagonists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Psychedelic space expanding on Trump’s EO
BioWorld
Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...